南模生物11月6日获融资买入272.14万元，融资余额7385.44万元

Core Viewpoint - Nanmo Bio experienced a slight decline in stock price, with significant financing activity indicating a high level of market interest and liquidity [1][2]. Group 1: Financial Performance - For the period from January to September 2025, Nanmo Bio achieved a revenue of 303 million yuan, representing a year-on-year growth of 14.29% [2]. - The net profit attributable to shareholders for the same period was 26.76 million yuan, showing a substantial year-on-year increase of 276.14% [2]. Group 2: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders for Nanmo Bio reached 6,687, an increase of 2.53% compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 2.47% to 11,658 shares [2]. - The company has distributed a total of 30.04 million yuan in dividends since its A-share listing, with 10.00 million yuan distributed over the past three years [3]. Group 3: Financing and Margin Data - On November 6, 2023, Nanmo Bio recorded a financing buy-in of 2.72 million yuan, while the financing repayment amounted to 4.31 million yuan, resulting in a net financing outflow of 1.59 million yuan [1]. - The total margin balance for Nanmo Bio as of November 6, 2023, was 73.85 million yuan, accounting for 2.10% of its market capitalization, which is above the 70th percentile of the past year [1]. - There were no short sales or borrowings on November 6, 2023, indicating a lack of bearish sentiment in the market [1].